The Orforglipron ACHIEVE Trials: Oral GLP-1 Efficacy

Orforglipron is Eli Lilly's oral non-peptide GLP-1. Here's what the ACHIEVE and ATTAIN trials show and when it's likely to launch.

Orforglipron is Eli Lilly's oral small-molecule GLP-1 receptor agonist — a non-peptide drug that, unlike oral semaglutide, does not require special absorption enhancers or restrictive administration protocols. The ACHIEVE and ATTAIN trial programs are the phase 3 registration-directed studies that will determine whether orforglipron becomes a commercially available oral alternative to injectable GLP-1s.

As of April 2026, orforglipron has generated substantial phase 2 and initial phase 3 data. The short summary: efficacy appears promising but modestly below injectable tirzepatide, the oral administration profile is much more user-friendly than oral semaglutide, and commercial launch could arrive in 2026-2027 pending regulatory review.

Why Orforglipron Matters

The existing oral GLP-1 option is oral semaglutide (Rybelsus for diabetes, oral Wegovy for weight management), which uses an absorption-enhancing excipient and requires daily morning dosing on an empty stomach with specific water volume and post-dose fasting. These requirements limit compliance and complicate real-world effectiveness. Orforglipron is a non-peptide small molecule that can be taken without food restrictions, at any time of day, with typical oral bioavailability. The practical usability is substantially better.

Phase 2 Results

Phase 2 trials of orforglipron in type 2 diabetes and in obesity without diabetes reported promising weight loss and glycemic control at multiple dose levels, with dose-dependent gastrointestinal tolerability. Results were sufficient to support phase 3 development across diabetes and weight-management indications.

ACHIEVE and ATTAIN Phase 3 Programs

Lilly released topline data from the early phase 3 trials showing favorable efficacy and tolerability. Mean weight loss in the ATTAIN obesity program was in the 12-15% range at top doses — meaningful, but below the roughly 20% observed with injectable tirzepatide. The comparison to injectable semaglutide (~15% in STEP 1) is closer, suggesting orforglipron may be competitive with injectable semaglutide on efficacy while offering oral administration without the oral-semaglutide usability constraints.

Tolerability Profile

Gastrointestinal adverse events — nausea, vomiting, diarrhea — are the dominant tolerability issue, consistent with the GLP-1 class. The phase 3 data has shown manageable GI tolerability with gradual dose titration. Discontinuation rates due to adverse events were in the expected range for the class. No unexpected safety signals have emerged at the phase 3 data cut.

The Commercial Positioning Question

If approved, orforglipron will enter a market already occupied by injectable tirzepatide (higher efficacy), injectable semaglutide (established, lower price now), oral Wegovy (lower price, usability constraints), and a pipeline of other oral and triple-agonist candidates. Orforglipron's likely positioning is as the most user-friendly oral option with efficacy competitive with injectable semaglutide — a meaningful clinical niche for patients who prefer oral dosing but want reliable absorption and flexible administration.

Pricing will matter. Injectable Wegovy at $349/month cash-pay and authorized telehealth at $249/month set the reference price that any new oral entrant will be benchmarked against. For orforglipron to gain significant market share, Lilly will need to price it competitively with both the oral and the injectable alternatives.

Regulatory Timeline

Lilly has indicated regulatory submission plans based on the ATTAIN and ACHIEVE programs. FDA review typically takes 10-12 months from submission for a drug of this class. Realistic commercial availability is mid-to-late 2026 at the earliest, with 2027 more likely depending on regulatory pathways. Coverage decisions, pricing announcements, and distribution partnerships would follow approval.

The Broader Oral GLP-1 Landscape

Orforglipron is one of several non-peptide oral GLP-1 candidates in development across the industry. Other programs from different manufacturers are in earlier stages. If orforglipron is the first to market with convincing efficacy and usable administration, it will define the oral GLP-1 category for several years before additional competitors arrive. For related reviews, see our oral Wegovy fact check and retatrutide phase 2 review.

Affiliate Disclosure: Some provider links on this page are affiliate links. If you sign up through these links, we may receive compensation at no additional cost to you. This does not influence our editorial content, pricing data, or provider selection.